Integration of numerical methods and microscale tools for kinetic characterisation. Synthetic biology principles for 'mix and match' expression of pairs of enzymes. Model predictions for the multi-enzymatic syntheses were verified experimentally. Reaction simulations were used to identify key process bottlenecks. Optimum conditions for fed-batch bioreactor operation were identified. a r t i c l e i n f o 
novo pathways are ultimately applied in vivo (as a whole cell biocatalyst) or in vitro (as isolated or immobilised enzymes), there is a need to understand the mechanisms of the enzymes involved and to model reaction kinetics in order to optimise the overall conversion yield. This can be particularly challenging when designing synthetic routes involving engineered enzymes and when using non-natural reactants as frequently encountered in industrial syntheses (Meyer et al., 2007) . In these cases appropriate reaction mechanisms must first be established and then kinetic parameters determined for multiple enzymes and a variety of potential starting reactants and pathway intermediates.
A particular target for de novo designed multi-step enzymatic conversions is the synthesis of complex chiral compounds from simple starting reactants (Roessner and Scott, 1996; Prather and Martin, 2008; Dalby et al., 2009 ). Ideally such reactants would be cheap, achiral and available from renewable sources (Keasling, 2010) . Products such as chiral amino-alcohols are of considerable industrial interest and represent an important target for multistep enzymatic syntheses. They are useful building blocks in the synthesis of a range of optically pure pharmaceuticals such as HIV protease inhibitors (Kaldor et al., 1997; Kwon and Ko, 2002) , active molecules such as (S)-amphetamine (Rozwadoska, 1993) or broad spectrum antibiotics like chloramphenicol and thiamphenicol (Bhaskar, 2004) .
Previously we have established a series of automated, microwell-based methods to inform early stage bioconversion process design and aid in quantitative prediction of larger scales process kinetics (Lye et al., 2003; Micheletti and Lye, 2006) . We have also established 'mix and match' expression systems to rapidly trial pairs of enzymes for use in de novo engineered pathways. The utility of this approach was illustrated for a sequential, two-step synthesis comprising carbon-carbon bond formation using a transketolase (TK), followed by a transaminase (TAm) to create chiral amino-alcohols from achiral substrates (Rios-Solis et al., 2011) . In that work the wild type Escherichia coli TK and the Chomobacterium violaceum 2025 (CV2025) TAm were selected for the one-pot synthesis of diastereoisomer (2S,3R)-2-amino-1,3,4-butanetriol (ABT) (Scheme 1), while the mutant E. coli TK D469E and the CV2025 TAm were selected for the synthesis of (2S,3S)-2-aminopentane-1,3-diol (APD) (Scheme 2). Nevertheless, the kinetic modelling and optimisation of multi-step biocatalytic processes has been poorly explored, due to the complexities of integrating the kinetic models for multiple enzymes and the number of kinetic parameters involved (Xue and Woodley, 2012) . Improved modelling and simulation would enable hypothetical changes to be explored in silico, speeding up process development and allowing the evaluation of process control strategies, to ensure stability and the desired efficiency (Sin et al., 2009) .
The aim of this work was to establish detailed kinetic models for each of the individual enzymatic reactions, exploiting our previously developed experimental methodologies, in order to optimise the overall conversion yields of ABT and APD (Schemes 1 and 2). Kinetic models for the various TK and TAm bioconversions were first obtained from microscale experimental data using previously established numerical techniques for rapid kinetic parameter determination (Chen et al., 2009; Rios-Solis et al., 2013) . These combine traditional initial rate experiments, to identify a solution in the vicinity of the global minimum, with nonlinear regression methods to determine the exact location of the solution thus reducing the number of experiments required. Once established, the kinetic models were validated against preparative scale (50 mL) bioconversion data before being used to identify key reaction constraints (Pollard and Woodley, 2007) and simulate scenarios for optimal bioreactor operation. These were again verified experimentally illustrating the importance of kinetic modelling to underpin the design and optimisation of multi-enzymatic systems in synthetic biology.
Materials and methods

Materials
Molecular biology enzymes were obtained from New England Bio-laboratories (NEB, Hitchin, UK). Nutrient broth and nutrient agar were obtained from Fisher Scientific (Leicestershire, UK). Scheme 2. Reaction scheme of the de-novo TK (D469E)-TAm pathway for the synthesis of chiral amino-alcohol (2S,3S)-2-aminopentane-1,3-diol (APD) from achiral substrates propionaldehyde (PA) and hydroxypyruvate (HPA). TK intermediate product is
Competent E. coli BL21-Gold (DE3) cells were obtained from Stratagene (Amsterdam, NL). All other reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless noted otherwise, and were of the highest purity available.
Synthesis of substrates and products
HPA was synthesised by reacting bromopyruvic acid with LiOH following a previously described method (Morris et al., 1996) . PKD was synthesised in a 100 mL scale bioconversion with 300 mM HPA, 300 mM PA, 9 mM MgCl 2 , 2.4 mM TPP, pH 7.0 and 30% v/v of D469E TK lysate (final TK concentration of 0.3 mg mL À 1 ). The reaction was stirred for 10 h at room temperature in a sealed flask and the pH was maintained at 7.0 using a 718 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland). The solution was dried on silica and purified by column chromatography (ethyl acetate: hexane, 1:1) to yield PKD as a colourless oil that crystallised on standing. ABT and APD product standards were prepared in a multi-step chemical synthesis described elsewhere (Ingram et al., 2007; Smith et al., 2010) .
Plasmids
2.3.1. Transketolase plasmid and mutagenesis Plasmid pQR412 contained the complete E. coli TK gene, tktA, with its native promoter and an N-terminal His6-tag. It was constructed using the expression vector pMMB67HE (8.8 kb), which has a RSF1010 origin of replication, the tac promoter, the Lac repressor and codes for resistance to ampicillin (Ingram et al., 2007) . Even though the plasmid contained the inducible tac promoter, the expression of the E. coli tktA was constitutive because of the presence of its native promoter. Site direct mutagenesis on the TK gene was performed using the Quikchange kit (Stratagene, Amsterdan, NL) following the supplier's instructions. The primers used for the TK mutagenesis were the following: D469E: TCGGTCTGGGCGAACAAGGGCCGACTCACCAG
Transaminase plasmid
Plasmid pQR801 contained the complete Chromobacterium violaceum 2025 TAm gene with a His6-tag (GenBank accession no. NP_901695). Plasmid pQR801 was constructed using the expression vector pET29(a) þ (5.3 kb), which contains an inducible T7 promoter, the Lac repressor and codes for resistance to kanamycin (Kaulmann et al., 2007) .
Biocatalyst preparation
2.4.1. Shake flask whole cell TK biocatalyst preparation Competent E. coli BL21-Gold (DE3) cells were transformed with the plasmid pQR412 using the heat shock technique described by the supplier (Stratagene, Amsterdam, NL). An overnight culture of the transformed cells was obtained in a 100 mL shake flask (10 mL working volume) of LB-glycerol broth (10 g L À 1 tryptone, 5 g L À 1
yeast extract, 10 g L À 1 NaCl and 10 g L À 1 glycerol) containing 150 mg L À 1 ampicillin. Growth was performed at 37 1C with orbital shaking at 250 rpm using an SI 50 orbital shaker (Stuart Scientific, Redhill, UK). The total volume of this culture was used to inoculate a 1 L shake flask (100 mL working volume) which was left to grow for 8 h. The cells were then harvested and following the removal of broth by centrifugation, they were resuspended in 200 mM HEPES buffer, pH 7.5 and used for whole cell bioconversions.
2.4.2. Shake flask whole cell TAm and TK-TAm biocatalyst preparation Transformation of E. coli BL21-Gold (DE3) cells with the plasmid pQR801 and inoculum preparation were performed in the same way as the TK biocatalyst, except that 150 mg L À 1 of kanamycin was used for the single transformed cells and 50 mg mL À 1 of both kanamycin and ampicillin were used for the double transformed strain. After inoculation of a 1 L shake flask (100 mL working volume), when the OD 600 reached a value of 1.5-2.0, isopropylthiogalactopyranoside (IPTG) was added to final concentration of 0.2 mM. After 4 h induction, the cells were harvested and following the removal of broth by centrifugation, they were resuspended in 200 mM HEPES buffer, pH 7.5 and used for whole cell bioconversions.
5 L fermentations
Batch fermentations were carried out in a 7.5 L fermenter (BioFlo 110, New Brunswick, Hertfordshire, UK) with a working volume of 5 l. The baffled fermenter had an aspect ratio of 1.79:1 and Rushton impellers (di/dt ¼0.25). The temperature was monitored by a thermocouple and automatically controlled at 30 or 37 1C via cold water circulation in the external jacket of the fermenter in addition to a heating jacket. The pH was measured by an Ingold gel filled pH probe (Ingold Messtechnik, Urdorf, Switzerland) and was controlled with the addition of 85% v/v H 3 PO 4 (acid) and 28% NH 4 OH v/v (base). DOT was monitored by a polarographic oxygen electrode (Ingold Messtechnik, Urdorf, Switzerland) and was maintained at 30% using control of the impeller speed and using gas blending with 100% oxygen when necessary. A solution of 80% polypropylene glycol was used as antifoam to control liquid levels using the automated antifoam probe. Ingoing air was sterilised by passage through a membrane filter and dispersed in the vessel at the base of the lower turbine with a ring sparger at a flow rate of 5 L min À 1 .
The vessel was filled with 4.5 L LB glycerol media with a composition as described in Section 2.4.1 and all the probe calibrations and pre-sterilization procedures were performed following the manufacturer instructions. The fermenter was then sterilised as a complete unit in an autoclave at 121 1C for 20 min, and after the media was cooled down, filter-sterilised ampicillin and kanamycin were added to a final concentration of 150 mg L À 1 .
The fermenter was then inoculated aseptically with five 100 mL shake flasks cultures previously grown overnight. Data was logged by on-line measurements of DOT, pH, temperature and speed of the impeller using the BioCommand software (BioFlo 110, New Brunswick, Hertfordshire, UK) as well as by taking regular optical density measurements at 600 nm (OD 600 ) using a spectrophotometer (Thermo Spectronic, Cambridge, UK).
2.5. Bioconversion kinetics 2.5.1. Automated microscale experimental platform Microscale bioconversions were performed in a glass 96-well, flat-bottomed microtiter plate with individual wells having a diameter of 7.6 mm and height of 12 mm (Radleys Discovery Technologies, Essex, UK). The microplate was covered with a thermo plastic elastomer cap designed to work with automated equipment (Micronic, Lelystad, Netherlands). All the bioconversions were performed using 300 ml total volume at 30 1C, pH 7.5 unless noted otherwise, and shaking was provided at 400 rpm with a Thermomixer Comfort shaker (shaking diameter of 6 mm, Eppendorf, Cambridge, UK) operated on the deck of a Tecan Genesis robotic platform (Tecan, Reading, UK). The concentration of TK cofactors MgCl 2 and thiamine pyrophosphate (TPP) were 9 mM and 2.4 mM respectively for all reactions. The concentration of TAm cofactor pyridoxal-5-phosphate (PLP) was 0.2 mM in all cases. Previous studies have shown that initial incubation with cofactor was necessary to allow the enzymes to bind to PLP or TPP (Ellis and Davies, 1961; Van Ophem et al., 1998) , therefore the whole cell suspension with the cofactor solutions were always added first in the well and left to incubate for 20 min at 30 1C, prior to initiation of the reaction with the addition of the substrate solutions. Aliquots of 20 μl were taken at various time intervals and quenched with 380 μl of a 0.1% v/v trifluoroacetic acid (TFA) solution. They were then centrifuged for 5 min at 5000 rpm and transferred into an HPLC vial for further analysis. All experiments were performed in triplicate. The specific activities were determined as the amount of PKD, ERY, acetophenone (AP), APD and ABT formed per unit of time normalised by the amount of enzyme used in the reaction.
Preparative scale bioconversions
Bioconversions at preparative scale (working volume of 50 mL) were performed in a 150 mL titration vessel with thermostat jacket (Metrohm Ion Analysis, Switzerland). Temperature was maintained at 30 1C using a circulating water bath (Grant Instruments, Cambridge, UK), mixing was achieved using a magnetic stirrer at 300 rpm, and the pH was maintained at pH 7.5 unless noted otherwise by the use of an automated addition of 1 M NaOH using a 718 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland). For preparative scale fed batch reactions, a peristaltic P-1 pump (Pharmacia Fine Chemicals, Uppsala, Sweden) was used to add the desired substrate solution over time.
Analytical methods
Biomass concentration was measured as optical density at 600 nm (OD 600 ) using a spectrophotometer (Thermo Spectronic, Cambridge, UK) and converted to dry cell weight (DCW) using a calibration curve where 1 OD 600 ¼0.4 g DCW L À 1 . Protein concentrations were obtained using Bradford assay and SDS-PAGE as described previously (Kaulmann et al., 2007) . A Dionex HPLC system (Camberley, UK) with a Bio-Rad Aminex HPX-87H reverse phase column (300 Â 7.8 mm 2 , Bio-Rad Labs., Richmond, CA, USA), controlled by Chromeleon client 6.60 software was used for the separation and analysis of PKD, ERY and HPA. The system comprised a GP50 gradient pump, a FAMOS autosampler, an LC30 chromatography column oven and an AD20 UV/vis absorbance detector and the method used has been described previously (Chen et al., 2009) . To quantify MBA, AP, APD and ABT, an integrated Dionex Ultimate 3000 HPLC system (Camberley, UK) with an ACE 5 C18 reverse phase column (150 mm Â 4.6 mm, 5 mm particle size; Advance Chromatography Technologies, Aberdeen, UK) controlled by Chromeleon client 6.60 software was employed and the method has been reported elsewhere (Kaulmann et al., 2007) . To analyse ABT and APD, the samples were derivatized by addition of an excess of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. The derivatizing reagent was made in house following a previously described protocol (Cohen and Michaud, 1993) , and the HPLC method used has been described previously (Ingram et al., 2007) . The enantiomeric excess (ee) of the ketodiols was determined by derivatization via dibenzoylation for satisfactory peak resolution by chiral HPLC, the method has been described in more detail elsewhere (Cázares et al., 2010) . Examples of the different HPLC profiles have been published previously (Rios-Solis et al., 2011).
Nonlinear regresion methods
A programme was developed using Matlab s software (MathWorks, Natick, MA, USA) in order to automatically perform all the nonlinear regressions and statistical analyses following the routines for kinetic parameter estimation as previously described (Chen et al., 2008; Rios-Solis et al., 2013) . All the nonlinear regressions were performed using the mesh adaptive pattern search algorithm in Matlab s known as: "The Genetic Algorithm and Direct Search Toolbox". This method was previously shown to be more likely to achieve global optimisation than gradient-based methods (Chen et al., 2008) . All kinetic parameters are reported as apparent values given that all enzymes are used in the form of whole cell biocatalysts.
Results
Determination of enzyme kinetic parameters
In our previous work, several enzyme candidates and biocatalyst forms were evaluated for their specific activities, final yield and enantiomeric excess for the synthesis of amino-alcohols (RiosSolis et al., 2011). The outcome was the construction of two whole cell biocatalysts; one comprising the E. coli wild type TK combined with the CV2025 TAm and the second comprising the mutant TK D469E combined with the CV2025 TAm for the synthesis of ABT and APD respectively (Schemes 1 and 2). The kinetic model and parameters for the TK synthesis of ERY from GA and HPA have been reported previously (Chen et al., 2009) , likewise for the TAm mediated synthesis of ABT from ERY and MBA (Rios-Solis et al., 2013) . In contrast the kinetic parameters for the TK D469E mediated synthesis of PKD and the subsequent CV2025 TAm mediated synthesis of APD were still unknown. Hence these kinetic parameters were determined here following the procedures described in our previous works (Chen et al., 2008; RiosSolis et al., 2013) .
TK kinetic models
Transketolase is an enzyme that catalyses carbon-carbon bond formation by transferring a C 2 moiety (1,2-dihydroxyethyl group) between a ketose sugar and an aldose sugar (Sprenger et al., 1995) The TK D469E catalysed synthesis of PKD from HPA and PA is an irreversible reaction due to the release of CO 2 as a side product (Scheme 2). The bioconversion follows a previously elucidated ping-pong bi-bi mechanism with competitive substrate inhibition, which requires thiamine pyrophosphate and Mg 2 þ as cofactors (Gyamerah and Willetts, 1997; Chen et al., 2008) . The full kinetic model can thus be written as follows:
where k cat represents the catalytic rate constant, K PA and K HPA are the Michaelis-Menten constants of PA and HPA, K iPA , K iHPA and K iPKD are the inhibition constants of PA, HPA and PKD respectively, and E iTK is the TK enzyme concentration. Note that the same kinetic model and equation applies for the synthesis of ERY, in which case the nomenclature for the keto-acceptor PA should be substituted by GA and product PKD by ERY. Following the methodology described in our previous work (Chen et al., 2008) , the values of the kinetic parameters were experimentally determined from microscale experimental data and are summarised in Table 1 . Fig. 1 shows the experimental Michaelis-Menten plots for the synthesis of PKD, as well as two progress curves with microscale experimental data and model predictions. The reliability and adequacy of the kinetic determination methodologies used in this work, as well as the validation of the TK model using GA have been performed elsewhere (Sayar et al., 2009a (Sayar et al., , 2009b . In that work, among the six kinetic parameters of the TK model, only 3 were found to display a positive effect on the performance of the reaction (positive sensitivity), which were the Michaelis-Menten constant for GA (K GA ), inhibition constant for HPA (K iHPA ), and the catalytic rate constant k cat . Excellent agreement was found between the experimental and predicted values ( Fig. 1c and d) . The apparent k cat for the synthesis of PKD using TK mutant D469E was found to be similar to the previously published value using E. coli TK mutant D469T in lysate form (Chen et al., 2008) . Interestingly, both Michaelis-Menten constants found in this work were half the value than the ones published for TK D469T. Although nonhydroxylated aliphatic aldehydes can be accepted by TK, the activity is typically very low (Cázares et al., 2010; Smith et al., 2010) . The variant TK D469E was engineered to work towards nonhydroxylated aliphatic aldehydes like PA; the result of a k cat value of 642 min À 1 is impressive, although it is still 5 times smaller than the wild type enzyme using hydroxylated aldehyde GA (Chen et al., 2009 ). The inhibition constants were found to be all in the same order of magnitude (Table 1 ). The enantiomeric excess of PKD was determined to be $ 90%, which was in agreement with previous works (Cázares et al., 2010 , Rios-Solis et al., 2011 .
TAm kinetic models
TAm catalyses enzymatic amino group transfer by a ping-pong bi-bi mechanism and requires the cofactor pyridoxal 5 0 -phosphate to catalyse the reaction (Bulos and Handler, 1965; Kuramitsu et al., 1990) . The reaction mechanism is composed of two half reactions, where in the first half reaction, the amino-donor binds to the enzyme and the amino group is transferred to the pyridoxal 5 0 phosphate cofactor, which forms pyridoxamine 5-phosphate (PMP), and the respective keto product is released. During the second half reaction, PMP (bounded to TAm) transfers the amino group to the acceptor substrate and PLP is regenerated, while the new aminated compound is released (Bulos and Handler, 1965) . It has been reported that in some TAm bioconversions substrate or product can bind an incorrect enzyme-cofactor form, creating dead end complexes that cannot react further, causing a potentially strong form of inhibition (Bulos and Handler, 1965; Kim, 1998, 2002) . For the CV2025 TAm mediated synthesis of APD, the presence of abortive complexes has not previously been shown. Therefore, a recently developed routine was experimentally applied to the TAm mediated synthesis of APD to elucidate the partially unknown reaction mechanism and the values of its parameters (Rios-Solis et al., 2013) . Substrate inhibition was found by the formation of the dead end complex E-PMP-MBA, which was in agreement with the form of inhibition exhibited in the TAm mediated synthesis of ABT using MBA as amino-donor (Rios-Solis et al., 2013) . The reaction mechanism is shown in Fig. 2 and the corresponding mathematical model is given in the following equation
where k f and k r represents the catalytic rate constants for the forward and reverse reaction respectively, K PKD , K AP , K APD and K MBA are the Michaelis-Menten constants of PKD, AP, APD and MBA, K iAPD and K iMBA are the inhibition constants of APD and MBA respectively, E iTAm represents the TAm concentration and K eq is the equilibrium constant. Again, it should be noted that the same kinetic model applies for the synthesis of ABT, and in the nomenclature the amino-acceptor PKD should be substituted by ERY and product APD by ABT. As for TK, the kinetic parameters were determined and are summarised in Table 2 . Fig. 3 shows the experimental Michaelis-Menten plots determined for both the forward and reverse reactions. The figure also shows two progress curves comparing microscale experimental data and model predictions for different initial substrate concentrations. Good agreement was again found between the experimental and predicted data (Fig. 3) . A more detailed discussion about the uncertainty and validation of the kinetic parameters has been performed previously for the TAm mediated synthesis of ABT (Rios-Solis et al., 2013) . In that work, a sensitivity analysis suggested a crucial bottleneck was the second half reaction of the ping pong bi-bi mechanism, in part due to the high Michaelis Menten constant of substrate ERY. The apparent forward catalytic 
Table 2
Experimentally established values of the apparent kinetic parameters for Eq. (2) for the synthesis of APD catalysed by a whole cell E. coli biocatalyst containing the CV2025 TAm. The parameters for APD synthesis were obtained experimentally following our previously described methodology and the parameters for ABT synthesis were obtained from literature (Rios-Solis et al., 2013 
95
Rate constant reverse reaction: k r k2 k6 k2 þ k6
12
(2) Michaelis-Menten constants (mM) Michaelis constant for MBA:
Amino-acceptor Michaelis constant:
Michaelis constant for AP:
Amino-alcohol Michaelis constant: (4) Equilibrium constants Global equilibrium constant: K eq k1 k3 k5 k7 k2 k4 k6 k8
843
Equilibrium constant for the first half reaction: K 1 k1 k3 k2 k4
275
Equilibrium constant for the second half reaction: K 2 k5 k7 k6 k8 22 3.1 rate constant for the TAm mediated synthesis of PKD was 3-fold smaller than the one reported for the synthesis of ERY (Rios-Solis et al., 2013) . In contrast, the Michaelis-Menten constant of PKD was 5 times smaller than the one determined for ABT synthesis, while the rest of the constants were in the same order of magnitude (Table 2 ). Simulations showed that by using the same enzyme concentration, the conversion rate of ERY by TAm to ABT would be relatively faster than the one of PKD to APD at concentrations above 200 mM. Nevertheless, at concentration below 30 mM, the low Michaelis-Menten constant of PKD compared to ERY would compensate the higher catalytic constant for ERY, giving comparable reaction rates for both amino-acceptors (simulation not shown).
Production of dual TK-TAm biocatalyst for the one-pot syntheses
When performing a multi-step biosynthesis, the choice of using pure enzymes or whole cells is fundamental to the design of the process. Using isolated enzymes involves higher upstream costs while whole-cell processes demands additional downstream costs (Woodley, 2006) . In the case of TAm, it was found to have better catalytic efficiencies in the whole cell form due to increased enzyme stability (Halim et al., 2014; Rios-Solis et al., 2013) . Although both TK and TAm biocatalysts could be added independently, so as to match their kinetic activities, this would double the cost of biocatalyst production. Furthermore, as progress is made to include larger numbers of enzymes in designed synthetic pathways then the efficiency of expression in a single host, with matched expression levels, will be critical for industrial implementation. The "mix and match" expression system, first proposed Hussain and Ward (2003) , would facilitate the necessary separate regulation of TK and TAm expression in E. coli being based on two plasmids with different origins of replication and antibiotic resistance genes (Rios-Solis et al., 2011).
Based on the above results, the k cat of TK was 17 or 25 times higher than the corresponding TAm k cat values in the de novo pathways to synthesise APD and ABT respectively (Tables 1 and 2 ). The optimum enzyme ratio would also depend on the concentration of the different substrates used but assuming an equimolar substrate ratio, due to the reaction stoichiometry, simulations showed the most effective TAm/TK ratio would be 19 and 12 for the ABT and APD one pot syntheses respectively.
In this work it was found that by manipulating the fermentation temperature and induction time, it was possible to modify the final TK and TAm concentration of the enzymes in the whole cell biocatalyst. Fig. 4 shows the expression profiles of TK and TAm during a 5 L fermentation at 30 and 37 1C with early and late exponential phase induction of TAm with IPTG (0.1 mM). It was found that by performing the 5 L fermentation at 37 1C with early exponential phase induction of TAm, it was possible to achieve a final biomass concentration of 8.5 70.5 g DCW L À 1 after 8 h of fermentation (specific growth rate of 0.437 0.07 h À 1 ). The final (Fig. 4a) , representing 39% and 7% respectively of the total cellular protein as determined by SDS PAGE (TAm/TK ratio of 6). Similar results were obtained for the dual TK D469E and the CV2025 TAm whole cell biocatalyst. This enzyme ratio was 2 and 3 times smaller than the optimum value determined for the synthesis of APD and ABT respectively. A fermentation performed at 30 1C with early induction achieved the highest TAm/TK ratio of 9 compared to the value of 6 obtained with the corresponding fermentation at 37 1C.
However, the high ratio at 30 1C was achieved due to a 43% decrease in TK expression compared to the result at 37 1C. This was not desirable for the one pot synthesis of amino alcohols, where a higher TAm/TK ratio is favourable. Overall, not only was the TK expression higher at 37 1C with early induction, but also the TAm expression was higher, making the biocatalyst produced at 37 1C with early induction economically more suitable for the multi-step synthesis of amino alcohols. These two dual TK-TAm whole cell biocatalysts were subsequently used for one-pot bioconversions at both microwell and preparative scales. (d) late exponential phase. The concentration of each enzyme was calculated assuming that 50% of the total dry cell biomass of E. coli cells were proteins (Watson, 1972) , and by obtaining the percentage of total protein of the corresponding enzyme by SDS-PAGE. Error bars represent one standard deviation about the mean (n ¼3).
Table 3
Comparison of the different bioreactors and reaction conditions used for operation of the multi-step syntheses using the two dual TK-TAm whole cell E. coli biocatalysts. 
Comparison of micro-and preparative scale one-pot bioconversion kinetics
After the individual kinetic models of all the enzymes were obtained, the one-pot syntheses of ABT and APD (Schemes 1 and 2) were experimentally performed in 300 ml parallel microwell bioconversions and in 50 mL working volume preparative scale bioconversions. This represented a 167-fold scale translation over which the previously established kinetic models could be validated. Table 3 compares the different conditions and bioreactor formats used. The main difference between the two scales of operation was that the pH of the preparative scale bioconversion was maintained at 7.5 by the use of automated pH-stat addition of 1 M NaOH in comparison to use of 200 mM HEPES buffer in the microscale system (Table 3) .
Modelling and scale-up of the one-pot synthesis of APD
Previous work has identified that the TAm amino-donor MBA could cause a side reaction when bioconversions were operated in a one-pot mode involving transfer of an amino group to the TK substrate HPA to yield serine (Rios-Solis et al., 2011) . To overcome this issue, MBA was subsequently added in a single fed-batch addition after the TK reaction was completed. For the one-pot synthesis of APD, the final whole cell biomass concentration used was 2.1 g DCW L À 1 , with TAm and TK concentrations of 0.4 and 0.07 mg mL À 1 respectively. The initial concentration of substrates PA and HPA were 10 mM, and using Eq. (1) it was predicted that the TK reaction would reach completion after 7 h, which was the time when TAm amino-donor MBA was added. A stock solution of 300 mM of the amino-donor was used, therefore the volume added of the MBA solution represented only 3% of the original reaction volume, and consequently the dilution of substrates and products was considered negligible. Fig. 5 shows the experimental progress curves of the micro and preparative scale multi-step synthesis of APD. Combining Eqs. (1) and (2), the complete modelling of the one-pot synthesis was also achieved. The microscale bioconversion kinetics generally show very good agreement with those from the preparative scale synthesis. A summary of the experimental kinetics and yields at the different scales and those from the model predictions is provided in Table 4 . The difference in TK and TAm specific activities of both scales were statistically not significant (Table 4 ). This indicates that the biocatalyst did not lose activity in the scale-up process, and also that the preparative scale synthesis did not suffer any mass transfer limitations. Excellent agreement was found between the predicted specific activities and the experimental data, which shows that the mathematical models developed using microscale data were still valid for preparative scale multi-step syntheses. After 1500 min of bioconversion, a small difference could be observed between the predicted and experimental data, which was higher than the experimental error, especially for the preparative scale synthesis. This discrepancy could also be detected in the final yield (% mol/mol) of the large scale bioconversion which was 7 and 13% smaller than the predicted and microscale data respectively. Because the predicted initial specific activities were in agreement with the experimental results of both scales (Table 4) , and the discrepancies only appeared after 1500 min of reaction, the difference in the final conversion was attributed to a decrease in stability of TAm, probably caused by the toxicity of MBA. Toxicity of the amino-donor towards TAm has also been reported in other works (Yun et al., 2004; Rios-Solis et al., 2013) . In addition, although APD was a non-natural substrate, consumption of APD by the whole cells could also contribute to the difference in yields, as it has previously been shown for similar amino-alcohols (Ingram et al., 2007) . Others who have investigated scale-up of TAm bioconversion from the ml to mL scale have reported a 30% difference in the final yield (% mol/mol) mainly attributed to pH fluctuations in the small scale system (Truppo et al., 2009 ). The use of 200 mM HEPES here enabled the maintenance of a constant pH thus helping to improve agreement between the different scales.
Modelling and scale-up of the one-pot synthesis of ABT
In the same way as for the one-pot synthesis of APD, the onepot synthesis of ABT (Scheme 1) was performed at the two scales. Due to the higher susceptibility of ERY and ABT to be consumed by side reactions in whole cell systems compared to PKD and APD (Ingram et al., 2007) , 25% less biomass concentration was used. Therefore the concentration of TK and TAm were 0.05 and 0.3 mg mL À 1 and the starting concentration of substrates GA and HPA was 30 mM. Eq. (2) predicted that after 250 min, the TK bioconversion would reach completion. After this time, MBA was added to a final concentration of 10 mM in the same way as for the synthesis of APD. An excess of ERY to MBA of 3:1 was maintained in the bioconversion due to the lower TAm Michaelis-Menten constant for ERY compared to MBA (Table 2) . This was done with the aim to speed-up the one-pot synthesis and avoids enzyme (1) and (2) with the corresponding kinetic parameters from Tables 1 and 2 . Error bars represent one standard deviation about the mean (n¼ 3).
Table 4
Experimental reaction rates and yields for the one-pot synthesis of APD shown in Fig. 5 based on microscale and preparative scale bioreactor data. The predicted values were obtained using Eqs. (1) and (2) with the kinetic parameters from Tables 1 and 2 deactivation by MBA, as well as ABT and ERY consumption by the whole cells. Fig. 6 shows the complete experimental progress curves of the micro and preparative scale bioconversions. Combining Eqs.
(1) and (2) with their respective parameters (Tables 1 and 2 ) again enabled modelling of the complete conversion profile. Good agreement was found between the two scales with a maximum experimental difference in ABT synthesis of 11%, which was not statistically significant. The kinetic results from the different scales and the model are summarised in Table 5. For this second bioconversion there was a 25% difference between the TK experimental and predicted specific activity (Table 5 ). This was probably because the TK kinetic model used from literature was established at 25 1C and pH 7.0 (Chen et al., 2009) , instead of 30 1C and pH 7.5 as used here. The difference was considered acceptable however, and good agreement could be concluded between the predicted and experimental data, validating the microscale mathematical models for preparative scale multi-step synthesis. As with the one-pot synthesis of APD, the ABT yield (% mol/mol) of the preparative scale conversion was 10 and 15% smaller than the microscale and predicted data (Table 5) . Also some consumption of ERY by the whole cell was observed in both scales (Fig. 6) . Nevertheless, by using an excess of 3:1 ERY: MBA, the reaction time to reach completion was reduced by 3 fold compared to an equimolar concentration of 10 mM (Eq. (1) and Table 1 ). The reduction in time allowed less consumption of ABT and ERY by the whole cells, as well as less inactivation of TAm by MBA.
3.4. Selection of optimum reactor operating conditions 3.4.1. One-pot synthesis of ABT with fed-batch addition of MBA Following validation of the bioconversion models, they were used to select the best reactor operating conditions to further increase the bioconversion yields. MBA was found to be inhibitory to TAm, which is in agreement with previous studies where problems with TAm were encountered at concentrations greater than 10 mM (Rios-Solis et al., 2013) . This limited the yield of the TAm bioconversion in equimolar concentrations above 10 mM. A solution to avoid MBA toxicity and inhibition is to use continuous fed-batch addition of the amino-donor. The Michaelis-Menten constant of ERY was found in previous work to be 97 mM in comparison with the one for MBA of 0.5 mM (Rios-Solis et al., 2013) . These values predicted that the production rate of ABT would not be severely affected by maintaining an MBA concentration below 10 mM in the bioconversion.
Consequently, a one-pot synthesis of ABT was performed at preparative scale with fed-batch addition of MBA. The initial volume of the bioconversion was 50 mL, and the pH and temperature were controlled at 7.5 and 30 1C. The initial concentration of HPA and GA was 100 mM which was 10 fold higher than in Fig. 5 . The concentration of TK and TAm were 0.75 and 0.14 mg mL À 1 respectively using a whole cell biocatalyst. To model the one-pot synthesis with fed-batch addition of MBA, Eqs. (1) and (2) were combined with the following differential equations to model the TAm step:
where R i (mM min ) is the rate of MBA solution added, MBAFeed (mM) is the concentration of MBA in the feed and Vol (l) is the working reaction volume.
Eq. (1) predicted that under the previously mentioned conditions, the TK reaction would reach completion after 180 min, at this time MBA was fed continuously as a 300 mM solution. A variable flow rate of the MBA solution that would match the predicted rate of the consumption of the amino-donor by Eq. (3) would have been desirable (Sayar et al., 2009a (Sayar et al., , 2009b , however this can be difficult to achieve in practice. Several simulations were thus performed using Eqs. (3)- (6) to identify an appropriate constant flow rate, which would maximise the reaction rate while maintaining a concentration of MBAo10 mM for the maximum possible time. The selected flow rate was 0.31 mL h À 1 , which combined with a calculated duration of the fed-batch operation of 53 h, meant that a total of 5 mmol of MBA would be added to the reaction equivalent to a normalised concentration of 100 mM for an initial reaction volume of 50 mL. Table 5 Experimental reaction rates and yields for the one-pot synthesis of ABT shown in Fig. 6 based on microscale and preparative scale bioreactor data. The predicted values were obtained using Eqs. (1) and (2) with the kinetic parameters from Tables 1 and 2 Tables 1 and 2 . Error bars represent one standard deviation about the mean (n¼ 3). Fig. 7 shows the experimental progress curves and the predicted normalised concentration for the one-pot synthesis of ABT with fedbatch MBA addition. In order to compare the performance of the different MBA addition modes, another one-pot synthesis using a single shot addition of 5 mmol of S-MBA (carefully added to allow the system to adjust pH) after 180 min was performed and is also shown in Fig. 7 . Reasonable agreement was found between the experimental and predicted data for the synthesis with fed-batch addition of MBA shown in Fig. 7 . After 2000 min, the consumption rate of MBA by TAm became less than the feed rate of MBA, therefore accumulation of the amino-donor started to occur. No further conversion was obtained after 3200 min; this was probably caused due to enzyme deactivation instead of an equilibrium constraint due to the high equilibrium constant determined for the bioconversion of 843 (Table 2 ). In the bioconversion with a single shot addition of MBA, as Eq. (2) predicted, the rate of ABT synthesis was initially faster than for the fed-batch bioconversion, resulting in higher ABT yields for the first 1000 min of reaction. Nevertheless, it appears TAm was totally inactivated after 1000 min by the higher concentration of MBA in comparison with the fed-batch bioconversion, and no further production of ABT was measured after that time. The result was a final conversion yield of 62% mol/mol for the bioconversion with fed-batch addition, which was 25% higher than the corresponding yield using the one shot addition of MBA.
3.4.2. One-pot synthesis of APD with fed-batch addition of IPA Although the bioconversions using MBA were determined not to be equilibrium controlled (Table 2) , the bioconversions did suffer from toxicity and inhibition problems of the amino-donor. IPA had shown great potential in microscale bioconversions at low substrate concentrations and was therefore selected as a new amino-donor (Rios-Solis et al., 2011) . In addition, any excess of IPA added in a fed-batch mode can be easily evaporated due to its high volatility .
Due to IPA evaporation using the microscale tools, it was not possible to obtain reliable data to determine the kinetic parameters with this substrate, nevertheless because the TAm reaction mechanism is divided into two half reactions, it was assumed that the Michaelis Menten constant of ERY and PKD was still high, and that inhibition and toxicity of the amino donor would still be present. Therefore, a preparative scale, one-pot synthesis of APD was performed with fed-batch addition of IPA. The initial concentration of PA and HPA were 200 mM (20 fold higher than the concentrations used in Fig. 5 ). The concentration of TK D469E and the CV2025 TAm were 0.75 and 0.14 mg mL À 1 using a whole cell biocatalyst. Using Eq. (1) and the kinetic parameters from Table 1 , it was predicted that the TK reaction would reach completion after 10 h. At that time, a solution of IPA 500 mM was fed continuously at a flow rate of 0.42 mL h À 1 during 48 h, so that a total amount of 10 mmol of IPA would be added to the vessel equivalent to a normalised concentration of 200 mM in 50 mL. Fig. 8 shows the experimental progress curve for normalised concentrations of HPA, PKD and APD, as well as the predicted data of the TK step (the TAm step was not modelled because the kinetic parameters using IPA were not determined in this work). Excellent agreement was found between the experimental and predicted TK data using Eq. (1), which validated the TK model for concentrations as high as 200 mM in a preparative scale synthesis. The TAm bioconversion did not seem to be inhibited by any accumulation of IPA during the 3000 min that the amino-donor was fed, suggesting that any excess of IPA evaporated away to below inhibitory levels. A total volume of IPA solution of 20 mL was added to the bioreactor, leading to a final APD yield of 70% mol/mol. This yield was 3.5 fold higher than the yield obtained for similar batch reaction conditions for a single TAm step bioconversion (data not shown). This suggested that fed-batch IPA addition could be overcoming inhibition or toxic effects on TAm activity at high concentrations. Table 6 shows a summary of the different bioreactor configurations, initial concentrations, amino-donor selection and final yields for the different preparative scale one pot syntheses of APD and ABT. Comparing these results with literature, a previous TK-TAm two step, preparative scale batch synthesis of APD (using 2 bioreactors) had achieved a final product concentration 37.8 mM from a starting TK substrate concentration of 300 mM (12.6% mol/ .
[TK] and [TAm] were 0.75 and 0.14 mg mL À 1 respectively in whole cell form. Kinetic profiles (dashed lines) of the TK step were modelled using Eq.
(1) with the corresponding kinetic parameters from Table 1. mol yield) . In that work 30% of TK intermediate (PKD) was lost due to product isolation, while a lower concentration of TAm substrates had to be used due to inhibition. Those problems were alleviated in this work where no isolation of TK intermediates was needed, and concentrations 1 order of magnitude higher of TAm substrates could be used due to the selected reaction conditions and reactor configuration. This allowed a final product concentration of 140 mM to be attained from initial TK reactant concentrations of 200 mM. This represents a 70% mol/mol conversion and a 6 fold greater yield than in the previous work.
Conclusions
The success of synthetic biology relies in great part in the characterisation and integration of the individual synthetic components. For a non-native, multi-enzymatic synthesis, the kinetic modelling of the individual steps is crucial to being able to "mix and match" the best enzymes and determine the best reactor configuration. This needs to be combined with a fine tuning of expression system to achieve the required individual enzyme concentrations. There are practically no studies where those kinetic analyses combined with synthetic biology tools were performed for cascade-type and one-pot catalytic reactions, hence limiting its speed development and application at the industrial scale. The microscale tools used here allowed those tasks to be performed with minimum resources and time, allowing a quantitative prediction of the reaction kinetics and substantial improvements over previously reported yields. Due to the advances in synthetic biology, the development of multi-step, one pot biocatalytic processes will increase and microscale kinetic modelling approaches as shown in this work will be crucial to speed technology translation to industrial scale. 
